BioCentury
ARTICLE | Company News

EC approves Lilly's imaging agent Amyvid

January 16, 2013 2:28 AM UTC

The European Commission approved Amyvid florbetapir from Eli Lilly and Co. (NYSE:LLY) as a PET imaging agent to estimate beta amyloid neuritic plaque density in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Lilly said it will begin discussions with reimbursement authorities in the "near future" and will launch the product in select territories next quarter.

Last year, FDA approved Amyvid, an imaging agent labeled with fluorine 18 (F-18) that binds to amyloid plaques, for the indication. Lilly gained the product through its acquisition of Avid Radiopharmaceuticals Inc. in 2010 (see BioCentury, April 9, 2012). ...